The emergence of WT1-specific t-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft- vs. -myeloma effect

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Tyler, Eleanor M ^a,b   Koehne, Guenther ^b,c  

^a Weill Cornell Medical Center   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Allogeneic stem cell transplantation; Donor lymphocyte infusion; Graft vs. myeloma effect; Multiple myeloma; WT1 specific cytotoxic T cells

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; LENALIDOMIDE; MESSENGER RNA; SYNDECAN 1; TUMOR ANTIGEN; WT1 PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; GENE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; POSTOPERATIVE INFECTION; RISK REDUCTION; T CELL DEPLETION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; WT1 GENE;

EID: 84886944312     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24963     Document Type: Article

References (10)

1. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-22; PMID:7751876
2. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, et al.; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195-203; PMID:21962393; http://dx.doi.org/10.1016/S1470- 2045(11)70243-1
3. van Heijst JW, Ceberio I, Lipuma LB, Samilo DW, Wasilewski GD, Gonzales AM, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med 2013; 19:372- 7; PMID:23435170; http://dx.doi.org/10.1038/ nm.3100
4. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. Nat Clin Pract Oncol 2006; 3:668- 81; PMID:17139318; http://dx.doi.org/10.1038/ ncponc0666
5. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362-4; PMID:14976044; http://dx.doi.org/10.1182/blood-2003-11-3862
6. Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, et al. Long-term follow-up of T celldepleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 2003; 9:312-9; PMID:12766881; http://dx.doi.org/10.1016/S1083- 8791(03)00075-2
7. Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant 2000; 25:623- 32; PMID:10734296; http://dx.doi.org/10.1038/ sj.bmt.1702187
8. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110:1924-32; PMID:17505014; http://dx.doi.org/10.1182/blood- 2007-03-076844
9. Tyler EM, Jungbluth AA, O'Reilly RJ, Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T celldepleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013; 121:308-17; PMID:23160468; http://dx.doi.org/10.1182/blood- 2012-06-435040
10. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-42; PMID:17875804; http://dx.doi.org/10.1182/blood-2007-08-108241